Spectrum Pharmaceuticals, Inc. (SPPI)
Stock Price:
$4.73 USD
0.17 (3.73%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $4.70 -0.03 (-0.63%) Nov 27, 4:56 PM
Key Info
| Market Cap |
690.21M |
| Revenue (ttm) |
109.33M |
| Net Income (ttm) |
-160.26M |
| Shares Out |
145.92M |
| EPS (ttm) |
-1.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$4.73 |
| Previous Close |
$4.56 |
| Change ($) |
0.17 |
| Change (%) |
3.73% |
| Day's Open |
4.61 |
| Day's Range |
4.57 - 4.79 |
| Day's Volume |
1,093,665 |
| 52-Week Range |
1.74 - 10.57 |
More Stats
| Market Cap |
690.21M |
| Enterprise Value |
491.90M |
| Earnings Date (est) |
Mar 10, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
145.92M |
| Float |
143.51M |
| EPS (basic) |
-1.36 |
| EPS (diluted) |
-1.37 |
| FCF / Share |
-0.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
12.86M |
| Short Ratio |
5.68 |
| Short % of Float |
8.96% |
| Beta |
2.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.31 |
| PB Ratio |
3.95 |
| Revenue |
109.33M |
| Operating Income |
-145.20M |
| Net Income |
-160.26M |
| Free Cash Flow |
-126.81M |
| Net Cash |
198.31M |
| Net Cash / Share |
1.36 |
| Gross Margin |
n/a |
| Operating Margin |
-132.81% |
| Profit Margin |
n/a |
| FCF Margin |
-115.98% |
| ROA |
-34.11% |
| ROE |
-80.17% |
| ROIC |
-168.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.80*
(128.33% upside)
Low
7.00
Current: $4.73
High
15.00
Target: 10.80
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | 146 | 163 | 187 | 156 | 268 | 193 | 74.11 |
| Revenue Growth | - | - | - | -9.91% | -12.99% | 19.88% | -41.78% | 38.73% | 160.36% | - |
| Gross Profit | - | - | - | 111 | 135 | 160 | 127 | 221 | 159 | 56.67 |
| Operating Income | -141 | -138 | -116 | -62.89 | -42.59 | -31.57 | -38.79 | 80.77 | 56.55 | -51.12 |
| Net Income | -113 | -121 | -92.19 | -69.77 | -52.64 | -45.72 | -62.13 | 94.20 | 49.93 | -47.06 |
| Shares Outstanding | 111 | 103 | 85.12 | 72.82 | 64.88 | 64.71 | 60.73 | 58.59 | 53.27 | 49.50 |
| Earnings Per Share | -1.02 | -1.17 | -1.08 | -0.96 | -0.81 | -0.71 | -1.02 | 1.46 | 0.86 | -0.95 |
| EPS Growth | - | - | - | - | - | - | - | 69.77% | - | - |
| Operating Cash Flow | -135 | -62.40 | -38.86 | -40.46 | 6.74 | -3.63 | -2.09 | 71.96 | 43.29 | -22.54 |
| Capital Expenditures | -8.97 | -0.11 | -0.47 | -0.08 | -0.22 | -25.93 | -0.16 | -0.31 | -0.48 | -1.58 |
| Free Cash Flow | -144 | -62.51 | -39.32 | -40.54 | 6.52 | -29.56 | -2.25 | 71.65 | 42.81 | -24.12 |
| Cash & Equivalents | 224 | 204 | 228 | 158 | 140 | 133 | 160 | 143 | 161 | 95.67 |
| Total Debt | - | - | 38.22 | 97.04 | 99.38 | 96.30 | 91.48 | 75.00 | 0.01 | 0.04 |
| Net Cash / Debt | 224 | 204 | 189 | 61.43 | 40.61 | 36.95 | 68.30 | 68.01 | 161 | 95.63 |
| Assets | 263 | 391 | 487 | 429 | 419 | 490 | 499 | 505 | 281 | 164 |
| Liabilities | 73.04 | 119 | 136 | 193 | 206 | 235 | 218 | 216 | 88.69 | 89.16 |
| Book Value | 190 | 271 | 351 | 236 | 213 | 255 | 282 | 289 | 192 | 74.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Spectrum Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
146 |
| CEO |
Joseph W. Turgeon |
Stock Information
| Ticker Symbol |
SPPI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SPPI |
| IPO Date |
September 26, 1996 |
Description
Spectrum Pharmaceuticals, a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNá, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.